Heartwire - Episode 145: Mortality benefit of running less than 20 miles per week; label update for dabigatran; who gets published?; alcohol may trigger AF episodes; FDA advisors: approve Sapien TAVR for high-risk operable patients

Summary: For the week ending June 15, 2012 we discuss the following top cardiology news from heartwire: • The not-so-long run: Mortality benefit of running less than 20 miles per week • Label update for dabigatran • Who gets published? Journals, conferences use different selection criteria • Alcohol may trigger AF episodes • Approve Sapien TAVR for high-risk operable patients, FDA advisors say And also, in brief: • "Safe enough": Arterial-thrombosis risk of hormonal contraceptives acceptable • Personalized website aids CV risk-factor control • Bonus info: CHADS2 helps predict post-CABG AF risk Join us for a comprehensive review of this week's most important cardiology news.